NCT06891703 - [18F]ACI-15916 PET in α-synucleinopathies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Parkinson's Disease (PD)Multiple System Atrophy (MSA)Dementia With Lewy Bodies (DLB)

Interventions

OTHER

[18F]ACI-15916

\[18F\]ACI-15916 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.

Trial Locations (1)

Unknown

RECRUITING

Karolinska Institutet, Solna